to the following vaccinate groups: (group 1) non- PPID horses, vaccinated IMa (n 12), (group 2) non-PPID controls, receiving a sterile saline vacci- nation (n3), (group 3) PPID horses (DP, n7; SP, n 7) vaccinated,a and (group 4) (n 6) PPID horses receiving sterile saline vaccine (DP, n 2; SP, n2). Peripheral blood for antibody titer mea- sures to EIV, equine herpesvirus (EHV)-1, and West Nile virus (WNV) were collected prior to the first vaccination (week 0) and again at week 2 and 4 post- vaccination. A second vaccinea or saline control was given at week 4 and blood collected at week 6 and week 8 post-vaccination.
3. Results
The results indicated that all horses receiving vac- cination responded significantly with an increase in EIV and EHV-1 antibody titers post-vaccination. Furthermore, the results indicated that there was
no significant difference in EIV antibody titers vac- cinations between non-PPID and PPID horses; how- ever, there were significant (p 0.05) differences in EHV-1 and WNV humoral immune responses among the PPID horses.
4. Discussion
This is the first study to determine the effects of PPID on immune responses to routine vaccination. Acknowledgments
Conflict of Interest
This project was funded by Boehringer Ingelheim Vetmedica.
Footnote a
Vetera® MO 64506. Gold, Boehringer Ingelheim Vetmedica, St. Joseph,
